N=28; relapsed or refractory CLL post-ibrutinib (arm A) or idelalisib (arm B); deletion 17p CLL (41%), deletion 11q CLL (55%), TP53-mutated (36%). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.